TMS for Veterans Attending a 2-week Intensive Outpatient Program for PTSD

Despite the efficacy of many evidence-based treatments for psychiatric disorders, a large percentage of treatment completers maintain their diagnosis and symptoms after treatment. For veterans with PTSD, approximately 66% of all individuals who successfully complete an evidence-based treatment retain their PTSD diagnosis.

An intervention that has been shown to be effective for non-response to first-line psychotherapies is transcranial magnetic stimulation (TMS). TMS is a safe, noninvasive intervention that uses a magnetic field to modulate cortical activity in brain areas linked to an overactive stress response. When compared to sham conditions which resembles the TMS condition but does not utilize any magnetic fields (i.e., proposed active ingredient), TMS has been associated with reduced depressive symptoms in treatment non-responders. Although the bulk of research examines TMS as a treatment for major depressive disorder, TMS has also shown promise in reducing symptoms of other psychiatric disorders such as PTSD.

In prior research TMS was associated with medium to large reductions in core PTSD symptoms when compared to sham conditions. Symptom reductions achieved via TMS have been demonstrated to persist. A recent study compared Cognitive Processing Therapy (CPT) combined with TMS to CPT with a sham condition and found that CPT combined with TMS was associated with greater PTSD symptom reductions during treatment and at six-month follow-up than CPT combined with a sham condition. This finding suggests that TMS may be beneficial as an augmentation to CPT. However, to our knowledge, previous literature has not yet examined whether TMS improves outcomes for individuals who are likely to not respond to CPT treatment.

Due to the demand for briefer TMS protocols, theta burst stimulation (iTBS) is a variation on TMS. Studies have found iTBS to be more efficient than standard TMS but still associated with significant improvements and low side effects in both depression and PTSD. The present study will utilize the more efficient iTBS protocol applied to the right dorsolateral prefrontal cortex (DLPFC) in order to reduce the length of stay for the participants.

Roughly one in four participants who complete Cognitive Processing Therapy (CPT) in the 2-week intensive outpatient program (IOP) at the Road Home Program at Rush do not report a meaningful reduction in PTSD symptoms and can be classified as non-responders. The present study seeks to determine whether adding iTBS to standard IOP programming is feasible for participants who have not reported reduced symptoms by the end of the first week of treatment (i.e., likely non-responders).

Inclusion criteria

• Veterans or service members between the ages of 18 and 65 who are attending the 2- week Intensive Outpatient Program at the Road Home Program and have not had significant PTSD symptom change based on the PCL-5 during the first week of treatment.
• Participants with an HDRS-21 score ≤ 26 at screening visit

Exclusion criteria

• Individuals with implants and non-removable metals which prevent them from safely receiving TMS, including:

• Aneurysm clips or coils
• Stents in the head, neck, or brain
• Deep brain stimulators
• Metallic implants in the head, neck, or brain (braces and dental implants do not interfere and are safe for TMS)
• Shrapnel or bullet fragments in or near the head
• Facial tattoos with metallic or magnetic-sensitive ink
• Other metal devices or ferromagnetic objects implanted in or near the head
• Pacemakers, intra-cardiac lines, or implanted medical pumps
• Individuals with a history of seizures or epilepsy (except those therapeutically induced by ECT)
• Individuals diagnosed with major, chronic mental health illnesses such as Psychotic Disorders, Bipolar Disorders, and Obsessive Compulsive Disorder
• Individuals with a history of substance abuse within the past six months
• Individuals with significant neurological disorders such as Parkinson's disease, Huntington's chorea, and Multiple sclerosis
• Individuals with unstable physical disease, such as unstable cardiac diseases
• Individuals currently on Benzodiazepine at a dose higher than 3mg or Lorazepam or equivalent.
• Women who are breastfeeding or pregnant
• Individuals with previous TMS treatment